Sign in

Tol Kohrman

Research Analyst at Craig-Hallum

Tol Kohrman is an Equity Research Analyst at Craig-Hallum specializing in the healthcare and biotechnology sectors, where he provides in-depth investment insights on companies such as Champions Oncology. He has demonstrated a strong focus on evaluating market trends, customer sentiment, and growth prospects for innovative healthcare firms. Since joining Craig-Hallum, Kohrman has actively participated in company earnings calls and sector analysis, leveraging his financial expertise to advise institutional investors. He holds relevant securities licenses and maintains FINRA registration, underscoring his professional credentials in equity research.

Tol Kohrman's questions to CHAMPIONS ONCOLOGY (CSBR) leadership

Question · Q1 2026

Tol Kohrman asked for insights into the broader investment landscape and customer trends, specifically regarding budget constraints and market improvements, and sought clarification on whether the stabilization period for revenue and margins is expected primarily in the first half of the current fiscal year.

Answer

CEO Rob Brainin characterized the investment environment as tough but cautiously optimistic, noting glimmers of hope as budget constraints ease and emphasizing Champions' strong positioning. CFO David Miller added that Q1 was likely the fiscal year's low point for revenue, with anticipated expansion in coming quarters, and highlighted data deals as a key driver, while acknowledging uncertainty on their exact timing.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts